Use of a clinical PET/CT scanner for whole body biodistribution of intranasal nanoparticles

Abstract

Whole body biodistribution of 100 nanometer sized polymer micellar nanoparticles (NPs) was determined following intranasal administration using PET/CT imaging on a clinical scanner. Nanoparticles labeled with Zirconium 89 were administered intranasally or intravenously to Sprague Dawley rats followed by serial ex vivo PET/CT imaging in a clinical scanner. At 30 minutes and 1 hour following intranasal delivery, the animals were sacrificed and placed in the PET/CT scanner. Images were acquired and transferred to a workstation for post-processing. 3D regions of interest were constructed. A different set of animals were used for ex vivo verification. These animals were also administered 100 nm polymer micellar NPs and sacrificed at 30 min and 1 hr following intranasal or intravenous delivery via intra-cardiac perfusion. Various organs, including brain, lungs, heart, liver, spleen, stomach and intestines, were procured following exsanguination. A gamma counter determined activity in each organ for comparison with corresponding PET/CT region of interest activity measurements. The ex vivo measurements of activity were consistent with the image-based value determinations. Use of a clinical PET/CT scanner is a feasible means to determine the temporal and spatial distribution of radiolabeled agents after intranasal and intravenous delivery. This work may allow for quantitative in vivo testing of new radionanotheranostic agents.